Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.61 USD | +0.29% | +6.36% | +51.65% |
05-03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
05-02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.65% | 2.36B | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating